AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The vaccine supply debate has distracted attention from strong growth at the company. I see the vaccine arguments as a sideshow. The company should make some money from the vaccines, but more importantly, its core businesses are in strong growth mode.

AstraZeneca: No Longer Overpriced

Hello, Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

Why AstraZeneca's vaccine will be too late for the US

They all have one thing in common: Efficacy beats the bar set by the FDA.

How Does the AstraZeneca Vaccine Measure Up to Rivals?

There's a lot more to AstraZeneca than poorly presented vaccine data.

Forget the Vaccine Problems, AstraZeneca Stock Can Still Make You Rich

The big drugmaker already has a major U.S. supply deal locked up if its vaccine obtains authorization.

Can AstraZeneca Win in the U.S. COVID Vaccine Market After Its Efficacy Results Fiasco?

iBio

Moderna

Novavax

Ocugen, Inc.

VanEck Vectors Pharmaceutical ETF

Sorrento Therapeutics Inc

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared first on InvestorPlace.

7 Pharmaceutical Stocks That Could Get a Covid Hangover

There are signs that Europe's diverging — and changing — usage rules when it comes to AstraZeneca's Covid vaccine are sowing further confusion among citizens.

'Everyone here is confused': Europe's see-sawing over AstraZeneca's vaccine is stoking doubts

NEW YORK, March 31, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca plc (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. SO WHAT: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN

Dr. Ashish Jha, a top US public-health expert, earlier this month laid out what he thought was an unpopular opinion. Shortly after AstraZeneca announced that its coronavirus vaccine was found to be safe and effective in a 32,000-volunteer US trial, Jha argued that the US should donate its supply of the shot to other countries, rather than reserve it for use domestically.

AstraZeneca's COVID-19 shot will come too late for the US

A U.S. government agency called out the drugmaker after it announced solid interim efficacy results.

How AstraZeneca Flubbed Its Better-Than-Expected COVID Vaccine Update

Germany has suspended use of the Covid vaccine created by AstraZeneca and the University of Oxford in the under-60s, dealing another blow to the drugmaker.

Germany suspends use of AstraZeneca's Covid shot for the under-60s, dealing another blow to drugmaker

Germany has suspended the use of the AstraZeneca COVID-19 vaccine for younger citizens over concerns of blood clotting, health officials announced on Tuesday. The AstraZeneca vaccine will not be administered to those under 60, unless they are in a high-risk category and agree to take the vaccine knowing the small risks of side effects.

Germany has suspended the use of the AstraZeneca vaccine for anyone under 60

Roku

AstraZeneca plc (NASDAQ: AZN) shares are trading lower by 2% after Berlin's state hospital halted the company's COVID-19 vaccination of women under the age of 55 years old. Last week, AstraZeneca issued a fresh update of its phase three trial data for the COVID-19 vaccine after a U.S. health agency earlier this week questioned the accuracy of the trial data.

What's Going On With AstraZeneca Stock And Roku Stock Today?

Berlin suspended the vaccine for under 60s after Germany reported more blood clot cases among those who had gotten the shot.

Germany To Reassess AstraZeneca Vaccine Amid Concern Over Blood Clots

India's drug regulator has allowed AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine to be used for up to nine months from its manufacture date, versus the prescribed six months, according to a document reviewed by Reuters and a source. The approval is expected to minimize vaccine wastage and better plan the inoculation programs.

India Extends Shelf Life For AstraZeneca COVID-19 Jab To Nine Months: Reuters

Canada has temporarily stopped giving AstraZeneca's COVID-19 vaccine to people under 55 while it investigates cases of an unusual blood-clotting disorder in Europe. Canadian officials said there were reports from Europe of a clotting disorder among some vaccinated people in Europe, particularly among young women, called Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT). In this disorder, antibodies "activate" platelets and cause blood clots to form.

Canada suspends the AstraZeneca vaccine in under-55s while officials investigate reports of rare blood clots

Germany's vaccine regulator said nine people have died from a rare blood clot in the brain after taking the AstraZeneca coronavirus vaccine, Reuters reported, citing a statement from the Paul Ehrlich Institute. Seven of the deaths were in women between 20 and 63 years old.

German regulator reportedly says nine have died from blood clots after taking AstraZeneca vaccine

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

The National Advisory Committee on Immunization recommendation came just days after the Canadian health department had backed the vaccine.

Canadian Panel Recommends Pausing AstraZeneca Vaccine For 55 And Younger

Colgate-Palmolive

Costco

Dollar General

Equinor

Target

Unilever

Safe stocks that have a low beta and hence low volatility. In addition, stocks that have a healthy dividend yield.

7 Safe Stocks to Buy If You're Allergic to Volatility

Los Angeles, California--(Newsfile Corp. - March 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - March 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

AZN Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

AstraZeneca stock was subject to wild swings in 2020 as the company pushed forward in developing a coronavirus vaccine. Now that the firm has authorization in the U.K., is AZN stock a buy?

Is AstraZeneca Stock A Buy As Shares Yo-Yo On Covid Vaccine Woes?

Could AstraZeneca Double Your Money Despite Vaccine Woes?

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 26, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) and reminds investors of the March 29, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in AstraZeneca stock or options...

News for AstraZeneca Stock (AZN)